These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Giacobini E Drugs Aging; 2001; 18(12):891-8. PubMed ID: 11888344 [TBL] [Abstract][Full Text] [Related]
23. Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease. de Andrade P; Mantoani SP; Gonçalves Nunes PS; Magadán CR; Pérez C; Xavier DJ; Hojo ETS; Campillo NE; Martínez A; Carvalho I Bioorg Med Chem; 2019 Mar; 27(6):931-943. PubMed ID: 30765302 [TBL] [Abstract][Full Text] [Related]
24. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Greig NH; Lahiri DK; Sambamurti K Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181 [TBL] [Abstract][Full Text] [Related]
25. The interactions of azure B, a metabolite of methylene blue, with acetylcholinesterase and butyrylcholinesterase. Petzer A; Harvey BH; Petzer JP Toxicol Appl Pharmacol; 2014 Feb; 274(3):488-93. PubMed ID: 24161345 [TBL] [Abstract][Full Text] [Related]
26. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Lane RM; Potkin SG; Enz A Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515 [TBL] [Abstract][Full Text] [Related]
27. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Rakonczay Z Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624 [TBL] [Abstract][Full Text] [Related]
28. Novel biphenyl bis-sulfonamides as acetyl and butyrylcholinesterase inhibitors: Synthesis, biological evaluation and molecular modeling studies. Mutahir S; Jończyk J; Bajda M; Khan IU; Khan MA; Ullah N; Ashraf M; Qurat-ul-Ain ; Riaz S; Hussain S; Yar M Bioorg Chem; 2016 Feb; 64():13-20. PubMed ID: 26595185 [TBL] [Abstract][Full Text] [Related]
29. Anticholinesterase and Antioxidant Activities of Natural Abietane Diterpenoids with Molecular Docking Studies. Topçu G; Akdemir A; Kolak U; Öztürk M; Boğa M; Bahadori F; Çakmar SDH Curr Alzheimer Res; 2020; 17(3):269-284. PubMed ID: 32329687 [TBL] [Abstract][Full Text] [Related]
30. Synthesis and molecular docking studies of 5-trifluoromethoxy-2-indolinones as cholinesterase dual inhibitors. Soylu-Eter Ö; Özsoy N; Karalı N Future Med Chem; 2024 Apr; 16(7):623-645. PubMed ID: 38470247 [No Abstract] [Full Text] [Related]
31. Discovery of novel isoflavone derivatives as AChE/BuChE dual-targeted inhibitors: synthesis, biological evaluation and molecular modelling. Feng B; Li X; Xia J; Wu S J Enzyme Inhib Med Chem; 2017 Dec; 32(1):968-977. PubMed ID: 28718678 [TBL] [Abstract][Full Text] [Related]
32. Combined QSAR, molecular docking and molecular dynamics study on new Acetylcholinesterase and Butyrylcholinesterase inhibitors. Daoud I; Melkemi N; Salah T; Ghalem S Comput Biol Chem; 2018 Jun; 74():304-326. PubMed ID: 29747032 [TBL] [Abstract][Full Text] [Related]
33. Cholinesterases: new roles in brain function and in Alzheimer's disease. Giacobini E Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140 [TBL] [Abstract][Full Text] [Related]
34. Highly selective inhibition of butyrylcholinesterase by a novel melatonin-tacrine heterodimers. Zawadzka A; Lozińska I; Molęda Z; Panasiewicz M; Czarnocki Z J Pineal Res; 2013 May; 54(4):435-41. PubMed ID: 24325732 [TBL] [Abstract][Full Text] [Related]
35. Novel ferulic amide derivatives with tertiary amine side chain as acetylcholinesterase and butyrylcholinesterase inhibitors: The influence of carbon spacer length, alkylamine and aromatic group. Liu H; Liu L; Gao X; Liu Y; Xu W; He W; Jiang H; Tang J; Fan H; Xia X Eur J Med Chem; 2017 Jan; 126():810-822. PubMed ID: 27951489 [TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease. Sang Z; Pan W; Wang K; Ma Q; Yu L; Yang Y; Bai P; Leng C; Xu Q; Li X; Tan Z; Liu W Eur J Med Chem; 2017 Apr; 130():379-392. PubMed ID: 28279845 [TBL] [Abstract][Full Text] [Related]
37. A Multi-layered Variable Selection Strategy for QSAR Modeling of Butyrylcholinesterase Inhibitors. Kumar V; De P; Ojha PK; Saha A; Roy K Curr Top Med Chem; 2020; 20(18):1601-1627. PubMed ID: 32543359 [TBL] [Abstract][Full Text] [Related]
38. Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease. Jiang X; Zhang Z; Zuo J; Wu C; Zha L; Xu Y; Wang S; Shi J; Liu XH; Zhang J; Tang W Eur J Med Chem; 2021 Nov; 223():113735. PubMed ID: 34371367 [TBL] [Abstract][Full Text] [Related]
39. Dual inhibition of acetylcholinesterase and butyrylcholinesterase enzymes by allicin. Kumar S Indian J Pharmacol; 2015; 47(4):444-6. PubMed ID: 26288480 [TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological activity of 1H-indene-2-carboxamides as multi-targeted anti-Alzheimer agents. Koca M; Yerdelen KO; Anil B; Kasap Z; Sevindik H; Ozyurek I; Gunesacar G; Turkaydin K J Enzyme Inhib Med Chem; 2016; 31(sup2):13-23. PubMed ID: 27226239 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]